The 4th World Congress on Controversies in Hematology (COHEM 2016)

Key Topics

• Non-Malignant Hematology
  • Coagulation Disorders
  • Haemoglobinopathies
  • Iron Deficiency - Overload
• Acute Leukemia / MDS
  • Should patients with AML / ALL receive prophylactic antibiotics and antifungal agents?
  • Should patients with RAEB oroligoblastic AML receive induction chemotherapy prior to allogeneic transplantation?
  • Should all patients with non Ph+ ALL transplantation in first CR?
• CLL
  • Are imaging techniques needed in the routine evaluation of newly diagnosed patients with CLL?
  • Is minimal residual disease a therapy end-point?
• Lymphoma
  • Should autologous transplantation be offered to all patients with Peripheral T Cell Lymphoma after induction therapy?
  • Should therapy be changed in patients with DLBCL if PET scan remain positive after 2 (or 4) courses of treatment?
• Myleofibrosis
  • Patients responding to Ruxolitinib should not be considered for allogeneic transplantation?
• Myeloma
  • Should bisphosphonates be continued indefinitely after chemotherapy is initiat
  • Patients with "high risk" myeloma who do not benefit from autologous transplant should be considered for allogeneic transplant?
• Hodgkin’s lymphoma
  • Should Brentuxumabbe moved to upfront therapy?
• CML
  • Should therapy be changed in patients with CML in chronic phase and "suboptimal" response after 6 months?
  • When generic imatinib becomes more available, should initial therapy be with imatinib or second generation tyrosine-kinase inhibitors?